TORONTO, Aug. 22, 2018 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has granted, effective today, an aggregate of 538,506 stock options (each an "Option") to certain directors, officers, employees and consultants of the Company in accordance with the Company's amended and restated stock option plan. Each Option is exercisable into one common share (a "Share") of the Company at a price of $8.34 per Share for a period of seven years from the date of grant, being today. The Options will vest in quarterly instalments over a four year period, beginning on the date that is twelve months from the date hereof.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE HLS Therapeutics Inc.
For further information: HLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, [email protected]